|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5288512A
(en)
|
1987-12-15 |
1994-02-22 |
The Procter & Gamble Company |
Reduced calorie fats made from triglycerides containing medium and long chain fatty acids
|
|
NL8800756A
(nl)
|
1988-03-25 |
1989-10-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Genetisch gemanipuleerde plantecellen en planten, alsmede daarvoor bruikbaar recombinant dna.
|
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
|
US5457189A
(en)
|
1989-12-04 |
1995-10-10 |
Isis Pharmaceuticals |
Antisense oligonucleotide inhibition of papillomavirus
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
FI924964A7
(fi)
|
1990-05-04 |
1992-11-03 |
Isis Pharmaceuticals Inc |
Geenien ilmentymisen muuntelu vaikuttamalla häiritsevästi RNA:n sekund aarirakenteeseen
|
|
IE66205B1
(en)
|
1990-06-14 |
1995-12-13 |
Paul A Bartlett |
Polypeptide analogs
|
|
US5650489A
(en)
|
1990-07-02 |
1997-07-22 |
The Arizona Board Of Regents |
Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
WO1992008796A1
(en)
|
1990-11-13 |
1992-05-29 |
Immunex Corporation |
Bifunctional selectable fusion genes
|
|
US6307040B1
(en)
|
1992-03-05 |
2001-10-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5474796A
(en)
|
1991-09-04 |
1995-12-12 |
Protogene Laboratories, Inc. |
Method and apparatus for conducting an array of chemical reactions on a support surface
|
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
ES2103918T3
(es)
|
1991-10-17 |
1997-10-01 |
Ciba Geigy Ag |
Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5605662A
(en)
|
1993-11-01 |
1997-02-25 |
Nanogen, Inc. |
Active programmable electronic devices for molecular biological analysis and diagnostics
|
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
|
IL101600A
(en)
|
1992-04-15 |
2000-02-29 |
Yissum Res Dev Co |
Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
|
|
US5288514A
(en)
|
1992-09-14 |
1994-02-22 |
The Regents Of The University Of California |
Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
|
|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
DE69332268T2
(de)
|
1992-10-15 |
2003-08-14 |
Toray Industries, Inc. |
Verfahren zur herstellung von rekombinant mhcii protein in mikroorganismen
|
|
EP1897942A1
(en)
|
1993-05-11 |
2008-03-12 |
The University Of North Carolina At Chapel Hill |
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
|
|
AU6953394A
(en)
|
1993-05-21 |
1994-12-20 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
|
US5491084A
(en)
|
1993-09-10 |
1996-02-13 |
The Trustees Of Columbia University In The City Of New York |
Uses of green-fluorescent protein
|
|
EP0889122A3
(en)
|
1993-11-30 |
1999-03-03 |
McGILL UNIVERSITY |
Inhibition of DNA Methyltransferase
|
|
US5908779A
(en)
|
1993-12-01 |
1999-06-01 |
University Of Connecticut |
Targeted RNA degradation using nuclear antisense RNA
|
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
|
US5593853A
(en)
|
1994-02-09 |
1997-01-14 |
Martek Corporation |
Generation and screening of synthetic drug libraries
|
|
EP0745134A1
(en)
|
1994-02-22 |
1996-12-04 |
Danafarber Cancer Institute |
Nucleic acid delivery system, method of synthesis and uses thereof
|
|
US5902880A
(en)
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
US6015880A
(en)
|
1994-03-16 |
2000-01-18 |
California Institute Of Technology |
Method and substrate for performing multiple sequential reactions on a matrix
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5525735A
(en)
|
1994-06-22 |
1996-06-11 |
Affymax Technologies Nv |
Methods for synthesizing diverse collections of pyrrolidine compounds
|
|
US5549974A
(en)
|
1994-06-23 |
1996-08-27 |
Affymax Technologies Nv |
Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
|
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
|
DE19502912A1
(de)
|
1995-01-31 |
1996-08-01 |
Hoechst Ag |
G-Cap Stabilisierte Oligonucleotide
|
|
IT1275862B1
(it)
|
1995-03-03 |
1997-10-24 |
Consiglio Nazionale Ricerche |
Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
|
|
IT1276642B1
(it)
|
1995-03-03 |
1997-11-03 |
Consiglio Nazionale Ricerche |
Trascritto antisenso presente in linfociti b ed oligodeossinucleotidi sintetici utili per inibirne l'azione
|
|
US5739311A
(en)
|
1995-06-07 |
1998-04-14 |
Gen-Probe Incorporated |
Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases
|
|
US5569588A
(en)
|
1995-08-09 |
1996-10-29 |
The Regents Of The University Of California |
Methods for drug screening
|
|
US20070173465A9
(en)
*
|
1995-10-11 |
2007-07-26 |
Monahan Sean D |
Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
|
|
KR19990082476A
(ko)
|
1996-02-14 |
1999-11-25 |
하우스 한스 루돌프, 긴터 베아트리체 |
당-변형되어 갭이 형성된 올리고뉴클레오티드
|
|
EP0888385B1
(en)
|
1996-03-14 |
2003-08-20 |
Genentech, Inc. |
Gdnf receptor and uses thereof
|
|
US5786213A
(en)
|
1996-04-18 |
1998-07-28 |
Board Of Regents, The University Of Texas System |
Inhibition of endogenous gastrin expression for treatment of colorectal cancer
|
|
US5756710A
(en)
|
1996-06-05 |
1998-05-26 |
The Trustees Of Columbia University In City Of New York |
Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
|
US7235653B2
(en)
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6013786A
(en)
|
1997-08-22 |
2000-01-11 |
Hybridon, Inc. |
MDM2-specific antisense oligonucleotides
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US6034883A
(en)
|
1998-01-29 |
2000-03-07 |
Tinney; Charles E. |
Solid state director for beams
|
|
US6175409B1
(en)
|
1999-04-02 |
2001-01-16 |
Symyx Technologies, Inc. |
Flow-injection analysis and variable-flow light-scattering methods and apparatus for characterizing polymers
|
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
|
US6221587B1
(en)
|
1998-05-12 |
2001-04-24 |
Isis Pharmceuticals, Inc. |
Identification of molecular interaction sites in RNA for novel drug discovery
|
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
|
EP1082012A4
(en)
|
1998-05-26 |
2002-01-16 |
Icn Pharmaceuticals |
NEW NUCLEOSIDES WITH BICYCLICAL SUGAR PART
|
|
US20030139359A1
(en)
|
2001-12-04 |
2003-07-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of phospholipid scramblase 3 expression
|
|
US6100090A
(en)
|
1999-06-25 |
2000-08-08 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of PI3K p85 expression
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
WO2000027424A2
(en)
|
1998-11-06 |
2000-05-18 |
Alcon Laboratories, Inc. |
Upregulation of endogenous prostaglandins to lower intraocular pressure
|
|
US5985663A
(en)
|
1998-11-25 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of interleukin-15 expression
|
|
CA2361251C
(en)
|
1999-01-27 |
2011-03-08 |
David L. Becker |
Formulations comprising antisense nucleotides to connexins
|
|
PT1152009E
(pt)
|
1999-02-12 |
2005-03-31 |
Sankyo Co |
Novos analogos de nucleosidos e oligonucleotidos
|
|
ATE385237T1
(de)
|
1999-02-26 |
2008-02-15 |
Univ British Columbia |
Antisense-therapie für trpm-2
|
|
US6617122B1
(en)
|
1999-03-15 |
2003-09-09 |
Xenon Genetics, Inc. |
Process for identifying modulators of ABC1 activity
|
|
US20040137423A1
(en)
|
1999-03-15 |
2004-07-15 |
Hayden Michael R. |
Compositions and methods for modulating HDL cholesterol and triglyceride levels
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
JP5095888B2
(ja)
|
1999-03-18 |
2012-12-12 |
エクシコン エ／エス |
特異的ｌｎａプライマによる遺伝子内における突然変異の検出
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
DK1163250T3
(da)
|
1999-03-24 |
2006-11-13 |
Exiqon As |
Forbedret syntese af [2.2.1]bicyclonukleosider
|
|
DE60038011T2
(de)
|
1999-04-08 |
2009-02-12 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
|
|
WO2000063365A1
(en)
|
1999-04-21 |
2000-10-26 |
Pangene Corporation |
Locked nucleic acid hybrids and methods of use
|
|
NZ514348A
(en)
|
1999-05-04 |
2004-05-28 |
Exiqon As |
L-ribo-LNA analogues
|
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
|
DE19925073C2
(de)
|
1999-06-01 |
2001-07-19 |
Stefan Weiss |
Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
AU781437B2
(en)
|
1999-06-25 |
2005-05-26 |
Serono Genetics Institute S.A. |
A novel BAP28 gene and protein
|
|
US20040006031A1
(en)
|
2002-07-02 |
2004-01-08 |
Isis Pharmaceuticals Inc. |
Antisense modulation of HMG-CoA reductase expression
|
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
|
WO2001021631A2
(en)
|
1999-09-20 |
2001-03-29 |
Millennium Pharmaceuticals, Inc. |
Secreted proteins and uses thereof
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US6528262B1
(en)
|
1999-10-06 |
2003-03-04 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger RNA
|
|
US6986988B2
(en)
|
1999-10-06 |
2006-01-17 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger RNA
|
|
AU2778801A
(en)
|
2000-01-07 |
2001-07-24 |
Baylor University |
Antisense compositions and methods
|
|
EP1252160B1
(en)
|
2000-01-14 |
2006-08-16 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Methanocarba cycloalkyl nucleoside analogues
|
|
US6303374B1
(en)
|
2000-01-18 |
2001-10-16 |
Isis Pharmaceuticals Inc. |
Antisense modulation of caspase 3 expression
|
|
JP2001247459A
(ja)
|
2000-03-03 |
2001-09-11 |
Oakland Uniservices Ltd |
癌の組み合わせ療法
|
|
US6936467B2
(en)
|
2000-03-27 |
2005-08-30 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
|
NZ521698A
(en)
|
2000-03-27 |
2004-08-27 |
Univ Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
|
US7402434B2
(en)
|
2000-05-08 |
2008-07-22 |
Newman Stuart A |
Splice choice antagonists as therapeutic agents
|
|
US20030176341A1
(en)
|
2000-06-29 |
2003-09-18 |
Jean-Francois Meritet |
Interferon-alpha induced gene
|
|
WO2002009700A1
(en)
|
2000-07-28 |
2002-02-07 |
Cancer Research Technology Limited |
Cancer treatment by combination therapy
|
|
US7053199B2
(en)
|
2000-08-29 |
2006-05-30 |
Takeshi Imanishi |
Nucleoside analogs and oligonucleotide derivatives containing these analogs
|
|
HUP0301805A3
(en)
|
2000-09-02 |
2005-12-28 |
Gruenenthal Gmbh |
Antisense oligonucleotides against vanilloid receptor 1
|
|
US6444464B1
(en)
|
2000-09-08 |
2002-09-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of E2F transcription factor 2 expression
|
|
AU2001289085A1
(en)
|
2000-09-20 |
2002-04-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of flip-c expression
|
|
EP1325121A2
(en)
|
2000-10-13 |
2003-07-09 |
Institut de Cardiologie de Montreal |
Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
|
|
US20030228618A1
(en)
|
2000-11-24 |
2003-12-11 |
Erez Levanon |
Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same
|
|
US20050222029A1
(en)
|
2001-01-04 |
2005-10-06 |
Myriad Genetics, Incorporated |
Compositions and methods for treating diseases
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US20020147165A1
(en)
|
2001-02-22 |
2002-10-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of calreticulin expression
|
|
EP1368458A2
(en)
|
2001-02-26 |
2003-12-10 |
Pharma Pacific Pty. Ltd. |
Interferon-alpha induced gene
|
|
AUPR497101A0
(en)
|
2001-05-14 |
2001-06-07 |
Queensland University Of Technology |
Polynucleotides and polypeptides linked to cancer and/or tumorigenesi
|
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
|
US7053195B1
(en)
|
2001-06-12 |
2006-05-30 |
Syngenta Participatious Ag |
Locked nucleic acid containing heteropolymers and related methods
|
|
ES2609014T3
(es)
|
2001-07-12 |
2017-04-18 |
University Of Massachusetts |
Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
|
|
US7153954B2
(en)
|
2001-07-12 |
2006-12-26 |
Santaris Pharma A/S |
Method for preparation of LNA phosphoramidites
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
|
WO2003020739A2
(en)
|
2001-09-04 |
2003-03-13 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
|
US20040214766A1
(en)
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
|
ATE318319T1
(de)
|
2001-10-10 |
2006-03-15 |
Nestle Sa |
Kaffeepflanze mit verringerter alpha-d- galaktosidase-aktivität
|
|
AR037699A1
(es)
|
2001-12-04 |
2004-12-01 |
Monsanto Technology Llc |
Maiz transgenico con fenotipo mejorado
|
|
US7125982B1
(en)
|
2001-12-05 |
2006-10-24 |
Frayne Consultants |
Microbial production of nuclease resistant DNA, RNA, and oligo mixtures
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
CA2365811A1
(en)
|
2001-12-21 |
2003-06-21 |
Institut De Cardiologie |
A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
|
|
KR20030056538A
(ko)
|
2001-12-28 |
2003-07-04 |
주식회사 웰진 |
리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
|
|
US20030191075A1
(en)
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
|
WO2003070157A2
(en)
|
2002-02-25 |
2003-08-28 |
Jacob See-Tong Pang |
Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
|
|
EP1483280B1
(en)
|
2002-03-08 |
2012-10-24 |
Glen Research Corporation |
Fluorescent nitrogenous base and nucleosides incorporating same
|
|
GB2386836B
(en)
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
|
US7169916B2
(en)
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
|
US20050215504A1
(en)
|
2002-04-02 |
2005-09-29 |
Bennett C F |
Antisense modulation of sterol regulatory element-binding protein-1 expression
|
|
SI2264172T1
(sl)
|
2002-04-05 |
2017-12-29 |
Roche Innovation Center Copenhagen A/S |
Oligomerne spojine za modulacijo izražanja HIF-1alfa
|
|
US6808906B2
(en)
|
2002-05-08 |
2004-10-26 |
Rigel Pharmaceuticals, Inc. |
Directionally cloned random cDNA expression vector libraries, compositions and methods of use
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
US20040033480A1
(en)
|
2002-08-15 |
2004-02-19 |
Wong Norman C.W. |
Use of resveratrol to regulate expression of apolipoprotein A1
|
|
EP1555870A4
(en)
|
2002-09-10 |
2006-11-02 |
Samuel Roberts Noble Found Inc |
METHOD AND COMPOSITIONS FOR PREPARING FLAVONOID AND ISOFLAVONOID UTILITY
|
|
US20060211640A1
(en)
|
2002-09-25 |
2006-09-21 |
Kane Christopher D |
Antisense modulation of farnesoid X receptor expression
|
|
AU2003278957A1
(en)
|
2002-09-26 |
2004-04-23 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
|
EP1562970A4
(en)
|
2002-11-01 |
2006-04-12 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR SIRNAIL INHIBITION OF HIF-1 ALPHA
|
|
AU2003261405A1
(en)
|
2002-11-01 |
2004-06-07 |
University Of Massachusetts |
Regulation of transcription elongation factors
|
|
GB2394658A
(en)
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
WO2004041889A2
(en)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
WO2004043979A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US20060009410A1
(en)
|
2002-11-13 |
2006-01-12 |
Crooke Rosanne M |
Effects of apolipoprotein B inhibition on gene expression profiles in animals
|
|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
US7339051B2
(en)
|
2003-04-28 |
2008-03-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
|
|
US7276599B2
(en)
|
2003-06-02 |
2007-10-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
SG146682A1
(en)
|
2003-09-18 |
2008-10-30 |
Isis Pharmaceuticals Inc |
Modulation of eif4e expression
|
|
WO2005038013A1
(en)
|
2003-10-07 |
2005-04-28 |
Isis Pharmaceuticals, Inc. |
Artisense oligonucleotides optimized for kidney targeting
|
|
EP1675948A2
(en)
|
2003-10-23 |
2006-07-05 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
|
|
JP4642775B2
(ja)
|
2003-12-23 |
2011-03-02 |
サンタリス ファーマ アー／エス |
Ｂｃｌ−２のモデュレーションのためのオリゴマー化合物
|
|
AU2005206794B2
(en)
|
2004-01-12 |
2010-09-16 |
The Trustees Of The University Of Pennsylvania |
Up-regulation of bone morphogenetic protein (BMP) gene expression in bone cells by electromagnetic signals
|
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
|
GB0403041D0
(en)
|
2004-02-11 |
2004-03-17 |
Milner Anne J |
Induction of apoptosis
|
|
EP1566202A1
(en)
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Use of resistin antagonists in the treatment of rheumatoid arthritis
|
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
|
WO2005113571A2
(en)
*
|
2004-05-13 |
2005-12-01 |
The University Of North Carolina At Chapel Hill |
Methods for the delivery of oligomeric compounds
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
US7297786B2
(en)
|
2004-07-09 |
2007-11-20 |
University Of Iowa Research Foundation |
RNA interference in respiratory epitheial cells
|
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
MX2007005558A
(es)
|
2004-11-09 |
2008-01-31 |
Santaris Pharma As |
Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
|
|
US7220549B2
(en)
|
2004-12-30 |
2007-05-22 |
Helicos Biosciences Corporation |
Stabilizing a nucleic acid for nucleic acid sequencing
|
|
EP1896084A4
(en)
|
2005-06-27 |
2010-10-20 |
Alnylam Pharmaceuticals Inc |
RNAI MODULATION OF HIF-1 AND THERAPEUTIC APPLICATIONS THEREOF
|
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
AU2006305886C1
(en)
|
2005-10-28 |
2011-03-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
|
WO2007056326A2
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
|
EP2641970B1
(en)
|
2005-11-17 |
2014-12-24 |
Board of Regents, The University of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
|
JP2009521408A
(ja)
|
2005-12-02 |
2009-06-04 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
|
|
CN101378764A
(zh)
|
2005-12-09 |
2009-03-04 |
贝勒研究院 |
通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
|
|
US20070213274A1
(en)
|
2005-12-20 |
2007-09-13 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
|
|
CN100356377C
(zh)
|
2005-12-20 |
2007-12-19 |
无锡永中科技有限公司 |
文档显示方法
|
|
JP5713377B2
(ja)
|
2005-12-28 |
2015-05-07 |
ザ スクリプス リサーチ インスティテュート |
薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
|
|
WO2007133812A2
(en)
*
|
2005-12-30 |
2007-11-22 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Improved carriers for delivery of nucleic acid agents to cells and tissues
|
|
CA2638906A1
(en)
*
|
2006-01-26 |
2007-08-16 |
University Of Massachusetts |
Rna interference agents for therapeutic use
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
ES2351674T3
(es)
|
2006-01-27 |
2011-02-09 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
|
|
CA2647728C
(en)
|
2006-03-31 |
2014-12-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
|
DK2021472T3
(da)
|
2006-05-05 |
2011-09-19 |
Isis Pharmaceuticals Inc |
Forbindelser og fremgangsmåder til modulering af genekspression
|
|
CA2651453C
(en)
|
2006-05-11 |
2014-10-14 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
|
EP1867338A1
(en)
|
2006-05-30 |
2007-12-19 |
Université Libre De Bruxelles |
Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
|
|
WO2008057556A2
(en)
|
2006-11-06 |
2008-05-15 |
Beth Israel Deaconess Medical Center |
Identification and use of small molecules to modulate ese-1 transcription factor function and to treat ese-1 transcription factor associated diseases
|
|
WO2008066672A2
(en)
|
2006-11-06 |
2008-06-05 |
Beth Israel Deaconess Medical Center |
Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
WO2008087561A2
(en)
|
2007-01-19 |
2008-07-24 |
Plant Bioscience Limited |
Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways
|
|
CA2686933A1
(en)
|
2007-04-06 |
2008-10-16 |
The Johns Hopkins University |
Methods and compositions for the treatment of cancer
|
|
US20080293142A1
(en)
|
2007-04-19 |
2008-11-27 |
The Board Of Regents For Oklahoma State University |
Multiple shRNA Expression Vectors and Methods of Construction
|
|
EP3486653A1
(en)
*
|
2007-05-24 |
2019-05-22 |
The United States Government as represented by The Department of Veterans Affairs |
Treatment of skeletal muscle disorder using ent2
|
|
WO2009044793A1
(ja)
*
|
2007-10-02 |
2009-04-09 |
Alphagen Co., Ltd. |
癌遺伝子を標的とするsiRNA
|
|
ES2563485T3
(es)
|
2008-07-01 |
2016-03-15 |
Monsanto Technology Llc |
Construcciones de ADN recombinante y procedimientos para modular la expresión de un gen diana
|
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Curna, Inc. |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
US8606289B2
(en)
|
2008-11-10 |
2013-12-10 |
Qualcomm Incorporated |
Power headroom-sensitive scheduling
|
|
EP2358382A2
(en)
|
2008-11-22 |
2011-08-24 |
The University of Bristol |
NOVEL USES OF VEGFxxxB
|
|
JP2012523225A
(ja)
*
|
2009-04-10 |
2012-10-04 |
アソシアシオン・アンスティテュ・ドゥ・ミオロジー |
疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
|